iCAD Launches New Version of VeraLook Computer-Aided Detection Technology for CT Colonography at ESGAR

Bichat Hospital in Paris Utilizing New Technology to Review Virtual Colonoscopy Images

NASHUA, N.H. & DRESDEN, Germany--(BUSINESS WIRE)-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced the launch of a new version of its VeraLook™ computer-aided detection (CAD) technology for CT colonography (CTC), or Virtual Colonoscopy. The new product, available in Europe under the CE Mark approval, will be launched at the 21st Annual Meeting of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), from June 2 – 5, 2010 in Dresden, Germany.

VeraLook detects and highlights potential polyps during CTC examinations. The newest version of VeraLook features performance improvements including a greater than 5% increase in the sensitivity of potential polyp detection, and a 20% reduction in false positives. In Europe, approximately 212,000 people die from colon cancer each year. When caught early, colon cancer is highly treatable but few patients recommended to be screened for colon cancer are actually tested. This reluctance can be directly linked in part to patients’ general discomfort with the traditional colonoscopy process.

Extensive testing with radiologists has demonstrated that the use of VeraLook improved reader sensitivity to all colonic polyps in a statistically significant manner – particularly for smaller, more easily missed polyps and pre-cancerous polyps which can develop into malignancies over time. VeraLook has also demonstrated high standalone sensitivity to detecting polyps, while generating a low number of clinically acceptable false positive marks on CTC images. Reader and standalone testing was conducted using exams containing various types of polyps including sessile, flat and pedunculated, and on patients prepped using different methodologies.

“VeraLook is already being sold commercially in Europe and Canada, and is an important tool in helping radiologists find colon cancers earlier and with greater confidence,” said Ken Ferry, president and CEO of iCAD. “Virtual colonoscopy with CAD is a breakthrough technology that can make this potentially life-saving test accessible to a greater number of people.”

Bichat Hospital in Paris has recently integrated the new VeraLook technology for CTC, used with a Viatronix V3D workstation, into its clinical practice. CTC employs cutting-edge, advanced visualization technology to produce three-dimensional images that permit a thorough and minimally invasive evaluation of the entire colorectal structure and is an accurate alternative to colonoscopy to detect polyps. Since it requires no sedation, patients undergoing a CTC exam are able to return to their normal activities immediately following the examination. VeraLook is pending FDA clearance in the U.S. and has been available in Europe since June 2009 under its initial CE Mark.

iCAD’s advanced imaging technologies will be featured at ESGAR at booth #3.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, more than 3,500 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.


For iCAD:
Darlene Deptula-Hicks, 603-882-5200 x7944
[email protected]
For Investor Relations:
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
[email protected]
For media inquiries:
Liza Heapes, 617-369-8787
[email protected]

KEYWORDS:   United States  Europe  North America  Germany  New Hampshire

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Biotechnology  Hospitals  Medical Devices  Oncology  Radiology